Chintan Sheth

I have a question on the U.S. side of the business where we have put out the numbers in terms of upcoming pipeline of 50 FTFs, 21 exclusive one s. If you can cumulatively provide some indication on the market size of those, and how should one look at monetizing those over the course of next three to five years?

On the EMEA side, and I believe the growth is coming because of the VISUfarma acquisition for last four quarters. Base of Q2 kind of bakes in the VISUfarma. How should one look at the growth in that piece, EMEA business going forward?

Any colour on the ROW market growth.